Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Alzheimer Disease: early-phase trial registry
155 of 312 indexed Alzheimer Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #25 of 28,707 conditions by registered trial count.
312 US clinical trials · 155 currently recruiting · #25 of 28,707 conditions by registered trial count
Alzheimer Disease: 312 US clinical trials tracked, 155 recruiting.
Alzheimer Disease is the subject of 312 registered US clinical trials on ClinicalTrials.gov, 155 of them currently open to new participants. 26 are in Phase 3-4 (later-stage) and 104 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 13 of these trials.
Enrollment posture brief
Registry condition alzheimer-disease
OPEN 155 | RECR 50% | LATE 26 | EARLY 104 | RANK #25 | SPON 13
Volume-matched condition peers
Nearest open-share peer: PTSD (50% recruiting · 155 trials)
Alzheimer Disease lists 155 open slots (50% of 312 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Alzheimer Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Alzheimer Disease is recruiting above its size-band peers.
155 of 312 indexed trials (49.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Alzheimer Disease trials is spread across many organizations.
Eli Lilly and Company accounts for 13 of 312 trials (4.2%). 178 distinct sponsors appear on at least one study for this condition label.
-
Typical Alzheimer Disease enrolment sits around 100 participants.
Median target enrolment is 100 among the 307 trials that report a genuine target (sentinel values excluded). 151 of those (49.2%) plan for fewer than 100 participants.
-
Alzheimer Disease research is mostly interventional.
255 interventional and 57 observational studies make up this index (81.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
312 total, page 2 of 7
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
Johns Hopkins University
NCT05795634
Cardiac-Control Affecting Learning Through Mindfulness (CALM)
University of Southern California
NCT06410157
Swallowing Impairments in Adults With and Without Alzheimer's Disease
Vanderbilt University Medical Center
NCT06678100
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
CereMark Pharma
NCT06254469
A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses
Arizona State University
NCT05877196
Improving Memory in Alzheimer's Disease With Noninvasive Brain Stimulation
Boston University Charles River Campus
NCT06094192
DORA and LP in Alzheimer's Disease Biomarkers
Washington University School of Medicine
NCT06274528
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
NeuroVision Imaging
NCT06400368
Sleep Trial to Prevent Alzheimer's Disease
Washington University School of Medicine
NCT04629547
Learning Skills Together Family Caregiver Complex Intervention
Case Western Reserve University
NCT05846984
Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People At Risk for Alzheimer's Disease
Massachusetts General Hospital
NCT05776641
[18F]PI-2620 Phase 3 Histopathological Study
Life Molecular Imaging
NCT05641688
The Role of the Locus Coeruleus in Age-related Distractibility
Virginia Polytechnic Institute and State University
NCT05574634
Paper-Based and Smartphone-Based Memory Supports
Baylor University
NCT06444841
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
Indiana University
NCT05733520
Clinical Trial on Agitation in Alzheimer's Dementia
IGC Pharma
NCT05543681
UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
University of Alabama at Birmingham
NCT03503331
UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy
University of Alabama at Birmingham
NCT03809351
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
University of Texas at Austin
NCT03082755
Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia
Stanford University
NCT04100057
The Locus Coeruleus, Norepinephrine and Cognitive Aging
Cornell University
NCT06880510
Early Age-Related Hearing Loss Investigation (EARHLI)
Columbia University
NCT06174038
Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia
Hebrew SeniorLife
NCT05661084
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
University of Virginia
NCT05565833
Dementia Care Partner Hospital Assessment Tool
University of Wisconsin, Madison
NCT05592366
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
Eli Lilly and Company
NCT06657768
Olfactory Biopsies
Duke University
NCT07021040
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Celgene
NCT06808984
LEADing Dementia End-of-Life Planning Conversations
University of Utah
NCT05909189
Brain Energy for Amyloid Transformation in Alzheimer's Disease Study
Wake Forest University Health Sciences
NCT03472664
Improving PCP Advance Care Planning for People With ADRD
University of Pittsburgh
NCT06565169
Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia
University of Texas at Austin
NCT06511752
The BRAIN App (Phase 2 SBIR)
Hopeful Aging
NCT06298474
Autoimmune Features of Neurodegenerative Disorders
Columbia University
NCT04239079
Repurposing Siponimod for Alzheimer's Disease
St. Joseph's Hospital and Medical Center, Phoenix
NCT06639282
Gut Microbiome and Blood Indices in Patients With AD and Their Spousal Caregivers
University of Virginia
NCT05601856
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
David Wilson
NCT05374278
Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease
Patrick Lao
NCT04576793
Vestibular Therapy in Alzheimer's Disease
Johns Hopkins University
NCT03799991
Studies of Brain and Body Interaction
Rutgers University
NCT03672266
Tau Networks in Psychotic Alzheimer's Disease
Northwell Health
NCT05847192
A Study of Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer's Disease
Mayo Clinic
NCT06057909
Apolipoprotein E (APOE) Genotype Effects on Triglycerides and Blood Flow in the Human Brain
University of Washington
NCT04692441
Treating Hyperexcitability in AD With Levetiracetam
Beth Israel Deaconess Medical Center
NCT03875638
Brain Outcomes With Lifestyle Change in Down Syndrome
University of Kansas Medical Center
NCT05985486
Investigation of Inflammation in Alzheimer's Disease and Related Dementias (ADRD) Using [11C]-CS1P1
Washington University School of Medicine
NCT06129838
Inspiring Seniors Towards Exercise Promotion to Protect Cognition
Emory University
NCT06496425
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
Alzheimer's Disease Expert Lab (ADEL)
NCT06247345
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
University of Pennsylvania
NCT05456503
Early-Stage Partner in Care Living Alone Plus
Arizona State University
NCT06962111
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 53 |
| Phase 2 | 51 |
| Phase 3 | 18 |
| Phase 4 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Alzheimer Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Alzheimer Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Alzheimer Disease page
312 registered trials, 155 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 155 Alzheimer Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Alzheimer Disease trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alzheimer Disease condition card totals 312 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.